Business Wire

ADVA

1.6.2022 09:02:07 CEST | Business Wire | Press release

Share
ADVA launches GPS-backup-as-a-service to help service providers combat GNSS cyberattacks

ADVA (FSE: ADV) today announced that it’s enabling service provider customers to offer GPS/GNSS-backup-as-a-service (GBaaS). A wide range of industries are increasingly reliant on satellite-delivered timing, but with threats including jamming and spoofing cyberattacks on the rise, operators need to find ways to safeguard services that rely on positioning, navigation, and timing (PNT) information. In-network timing based on NTP and PTP is also increasingly vulnerable to cyber threats. As a response, ADVA is now empowering service providers to offer GBaaS and enable end users to address new guidelines and standards for redundant PNT architectures. GBaaS meets the latest recommendations for PNT homeland security like US Executive Order 13905. Leveraging ADVA’s aPNT+™ technology , it eliminates the risks and costs associated with GNSS dependence.

“Threats to hamper PNT capabilities are growing, and much of the world’s critical infrastructure is still without adequate protection from GNSS vulnerabilities. All of that can change when service providers are able to offer GBaaS. It’s based on our aPNT+ platform, which leverages a suite of technologies, including multi-band GNSS receivers and AI- and ML-based management software. As well as making networks more resilient against cyberattacks, our aPNT+ platform also delivers highly accurate backup when GNSS fails,” said Gil Biran, GM of Oscilloquartz, ADVA. “Now service providers can offer ADVA’s aPNT+ protection as a subscription-based service as part of their SLAs. This will enable many more timing networks to achieve very high levels of resilience and assurance. Across a wide range of industries, this will be the easiest and most flexible way to guarantee robust PNT services.”

ADVA’s GBaaS solution employs a combination of multi-layer detection, multi-source backup and fault-tolerant mitigation to render timing networks more secure. Embedded in all timing devices, ADVA’s Syncjack technology provides comprehensive and precise synchronization performance monitoring and analytics, enabling the Ensemble Sync Director network management suite to intelligently operate and prioritize multi-source timing feeds across the network. Onboard multi-band GNSS receivers boost timing accuracy and also protect against attacks like jamming and spoofing. But for those times when GNSS is either unavailable or compromised, a dispersed network of autonomous cesium atomic clocks and network backup timing feeds is always sitting on standby, ready to deliver highly accurate network timing over long periods of GNSS unavailability.

“GBaaS is a completely new way for service providers to sell critical PNT infrastructure as a service without the burden of investment and maintenance. For the first time, they can offer their customers SLAs at a range of levels that ensure the resilient and assured timing needed across time-sensitive networks and applications,” commented Nino De Falcis, senior director of business development at Oscilloquartz, ADVA. “The flexibility and protection that GBaaS affords is bad news for any malicious actors looking to attack PNT services. Service providers can now offer their customers a guarantee: When GNSS is compromised or goes offline, ADVA’s robust network of defense-in-depth PTP timing devices will be there to provide the accuracy and backup they urgently need.”

Further information on ADVA’s GBaaS solution is available in these slides: https://adva.li/gbaas-slides .

About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye